How to Counsel Breastfeeding Patients on Viloxazine ER
How should clinicians counsel a breastfeeding patient with ADHD who is taking or considering viloxazine extended-release?
Breastfeeding patients with attention-deficit/hyperactivity disorder may need ongoing pharmacotherapy postpartum, but lactation data for ADHD medications are often sparse. This study directly addresses how much viloxazine extended-release transfers into breast milk at the maximum recommended adult dose and provides estimated infant exposure values that can be used in a clinical risk-benefit discussion.
-
Confirm that the study population matches the patient reasonably well
Use these data as most applicable to healthy lactating women 18 to 45 years old who were 12 weeks to 2 years postpartum with a healthy-term infant. The study participants received viloxazine extended-release 600 mg once daily for 3 consecutive days, so the findings are anchored to short-term steady-state exposure at the maximum recommended adult dose rather than lower doses or a broader medically complex population.
-
Explain that viloxazine transfer into breast milk was low
Tell the patient that viloxazine was detected in breast milk at low concentrations relative to maternal plasma. At steady state on Day 3, the geometric mean breast milk-to-plasma exposure ratio was 0.338, the geometric mean breast milk AUC over 24 hours was 21.4 µg•h/mL, and the geometric mean peak milk concentration was 1.41 µg/mL, reached at a median of 5.53 hours after dosing.
-
Quantify estimated infant exposure using the study values
Counsel with the article's infant exposure estimates rather than general impressions alone. The geometric mean daily infant dose present in milk in this study was 0.511 mg/day, about 0.09% of the maternal 600 mg/day dose; the estimated daily infant dose was 0.134 mg/kg/day using 150 mL/kg/day milk intake and 0.178 mg/kg/day using 200 mL/kg/day for early infancy.
-
Interpret the relative infant dose in context
Use relative infant dose as the main standardized counseling metric from the article. The weight-adjusted relative infant dose was 1.53% using 150 mL/kg/day milk intake and 2.04% using 200 mL/kg/day, which the authors note is well below the less-than-10% threshold that lactation specialists and updated American College of Obstetricians and Gynecologists guidance generally consider acceptable for breastfeeding.
-
Note that the major metabolite contributed negligible milk exposure
If discussing total pharmacologic exposure, mention that the major metabolite 5-HVLX-gluc had negligible transfer into breast milk. The article reports an approximate relative infant dose of 0.1% for this metabolite and describes it as inactive.
-
Discuss maternal tolerability observed in the study
Include maternal adverse effects in the counseling discussion because postpartum treatment decisions depend on both infant exposure and maternal tolerability. In this study, 12 of 15 participants reported 28 adverse events, all mild and resolved by study end; no serious adverse events occurred and no participant discontinued, with somnolence the most common adverse event, followed by dizziness, nausea, breast tenderness, headache, and dry mouth.
-
Frame the final decision as a risk-benefit discussion
Conclude by weighing the potential risk of infant exposure against the mother's clinical need for viloxazine extended-release and the developmental and health benefits of breastfeeding, exactly as the article advises. Make clear that the overall conclusion of Pharmacokinetics of Viloxazine ER (Viloxazine Extended-Release Capsules) in Breast Milk of Healthy Lactating Women is that transfer into breast milk was low, while also acknowledging that infant outcome data were not collected.
Clinical Considerations
- The study did not evaluate effects on breastfed infants because infants were not enrolled.
- The data come from 15 healthy lactating women studied under controlled inpatient conditions, which may not reflect real-world breastfeeding patterns.
- Milk production varied widely among participants, with a median Day 3 volume of 543 mL and a range of 182 to 1,259 mL, so individual infant exposure may differ.
- These findings were generated after 3 consecutive days of viloxazine extended-release 600 mg daily and may not directly characterize other doses or longer-term use.
Bottom Line
When counseling a breastfeeding patient about viloxazine extended-release, the key message from this study is that milk transfer and estimated infant exposure were low, with a relative infant dose of about 1% to 2%, well below the commonly cited 10% threshold.
